
Insmed (INSM) Stock Forecast & Price Target
Insmed (INSM) Analyst Ratings
Bulls say
Insmed Inc. is showing strong potential for growth based on increased revenue estimates and a revised outlook on its product pipeline, notably with Brensocatib expected to generate approximately $8.5 billion in peak sales by 2033. The company has also introduced revenue estimates for Treprostinil Palmitil Inhalation Powder (TPIP), further enhancing its market prospects in the treatment of interstitial lung disease and pulmonary arterial hypertension. Additionally, a decreased terminal decline rate in the discounted cash flow (DCF) calculation reflects heightened confidence in the long-term viability and profitability of Insmed's innovative therapies.
Bears say
Insmed Inc faces significant uncertainty due to potential delays in enrolling and completing clinical studies for its key products, Arikayce, Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP), which could negatively impact the company's probability of success and overall valuation. Additionally, projections indicate that TPIP may not enter the idiopathic pulmonary fibrosis (IPF) market before 2034, contingent on the approval of a competing product, Tyvaso, in 2027, due to orphan drug exclusivity considerations. These factors contribute to a cautious outlook on Insmed's financial stability and growth potential in the near to medium term.
This aggregate rating is based on analysts' research of Insmed and is not a guaranteed prediction by Public.com or investment advice.
Insmed (INSM) Analyst Forecast & Price Prediction
Start investing in Insmed (INSM)
Order type
Buy in
Order amount
Est. shares
0 shares